210 related articles for article (PubMed ID: 27786097)
1. The effects of vasoactive intestinal peptide in neurodegenerative disorders.
Deng G; Jin L
Neurol Res; 2017 Jan; 39(1):65-72. PubMed ID: 27786097
[TBL] [Abstract][Full Text] [Related]
2. Vasoactive intestinal peptide prevents activated microglia-induced neurodegeneration under inflammatory conditions: potential therapeutic role in brain trauma.
Delgado M; Ganea D
FASEB J; 2003 Oct; 17(13):1922-4. PubMed ID: 12923064
[TBL] [Abstract][Full Text] [Related]
3. [Neuroprotective role of PACAP, VIP, and PHI in the central nervous system].
Sokołowska P; Dejda A; Nowak JZ
Postepy Hig Med Dosw (Online); 2004; 58():416-27. PubMed ID: 15577749
[TBL] [Abstract][Full Text] [Related]
4. Vasoactive intestinal peptide protects against beta-amyloid-induced neurodegeneration by inhibiting microglia activation at multiple levels.
Delgado M; Varela N; Gonzalez-Rey E
Glia; 2008 Aug; 56(10):1091-103. PubMed ID: 18442091
[TBL] [Abstract][Full Text] [Related]
5. From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP: a view of neuroprotection and cell division.
Gozes I; Divinsky I; Pilzer I; Fridkin M; Brenneman DE; Spier AD
J Mol Neurosci; 2003; 20(3):315-22. PubMed ID: 14501014
[TBL] [Abstract][Full Text] [Related]
6. VIP and peptides related to activity-dependent neurotrophic factor protect PC12 cells against oxidative stress.
Steingart RA; Solomon B; Brenneman DE; Fridkin M; Gozes I
J Mol Neurosci; 2000 Dec; 15(3):137-45. PubMed ID: 11303778
[TBL] [Abstract][Full Text] [Related]
7. Role of vasoactive intestinal peptide in inflammation and autoimmunity.
Gonzalez-Rey E; Delgado M
Curr Opin Investig Drugs; 2005 Nov; 6(11):1116-23. PubMed ID: 16312132
[TBL] [Abstract][Full Text] [Related]
8. Protective peptides derived from novel glial proteins.
Brenneman DE; Spong CY; Gozes I
Biochem Soc Trans; 2000; 28(4):452-5. PubMed ID: 10961938
[TBL] [Abstract][Full Text] [Related]
9. Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activation.
Delgado M; Ganea D
FASEB J; 2003 May; 17(8):944-6. PubMed ID: 12626429
[TBL] [Abstract][Full Text] [Related]
10. Neuroprotection against neurodegenerative diseases: development of a novel hybrid neuroprotective peptide Colivelin.
Chiba T; Nishimoto I; Aiso S; Matsuoka M
Mol Neurobiol; 2007 Feb; 35(1):55-84. PubMed ID: 17519506
[TBL] [Abstract][Full Text] [Related]
11. VIP in neurological diseases: more than a neuropeptide.
Morell M; Souza-Moreira L; González-Rey E
Endocr Metab Immune Disord Drug Targets; 2012 Dec; 12(4):323-32. PubMed ID: 23094829
[TBL] [Abstract][Full Text] [Related]
12. Neuronal release of vasoactive intestinal peptide is important to astrocytic protection of neurons from glutamate toxicity.
Brown DR
Mol Cell Neurosci; 2000 May; 15(5):465-75. PubMed ID: 10833303
[TBL] [Abstract][Full Text] [Related]
13. Vasoactive intestinal peptide prevents excitotoxic cell death in the murine developing brain.
Gressens P; Marret S; Hill JM; Brenneman DE; Gozes I; Fridkin M; Evrard P
J Clin Invest; 1997 Jul; 100(2):390-7. PubMed ID: 9218516
[TBL] [Abstract][Full Text] [Related]
14. VIP neurotrophism in the central nervous system: multiple effectors and identification of a femtomolar-acting neuroprotective peptide.
Brenneman DE; Glazner G; Hill JM; Hauser J; Davidson A; Gozes I
Ann N Y Acad Sci; 1998 Dec; 865():207-12. PubMed ID: 9928014
[TBL] [Abstract][Full Text] [Related]
15. Brain mast cells and therapeutic potential of vasoactive intestinal peptide in a Parkinson's disease model in rats: brain microdialysis, behavior, and microscopy.
Tunçel N; Sener E; Cerit C; Karasu U; Gürer F; Sahintürk V; Bayçu C; Ak D; Filiz Z
Peptides; 2005 May; 26(5):827-36. PubMed ID: 15808913
[TBL] [Abstract][Full Text] [Related]
16. VIP-induced neuroprotection of the developing brain.
Passemard S; Sokolowska P; Schwendimann L; Gressens P
Curr Pharm Des; 2011; 17(10):1036-9. PubMed ID: 21524251
[TBL] [Abstract][Full Text] [Related]
17. [Protective effects of vasoactive intestinal peptide on septic shock rats].
Qiu JF; Zhang ZQ; Chen W; Wu ZY
Zhonghua Wai Ke Za Zhi; 2007 Feb; 45(3):196-9. PubMed ID: 17498382
[TBL] [Abstract][Full Text] [Related]
18. Vasoactive intestinal peptide reduces the inflammatory profile in mice infected with Trypanosoma cruzi.
Higyno PM; Mendes PF; Miranda MB; Pereira DE; Mota AP; Nogueira Kde O; Caldas IS; Moura SA; Menezes CA
Exp Parasitol; 2015 Dec; 159():72-8. PubMed ID: 26358268
[TBL] [Abstract][Full Text] [Related]
19. Vasoactive intestinal peptide family as a therapeutic target for Parkinson's disease.
Gonzalez-Rey E; Chorny A; Fernandez-Martin A; Varela N; Delgado M
Expert Opin Ther Targets; 2005 Oct; 9(5):923-9. PubMed ID: 16185148
[TBL] [Abstract][Full Text] [Related]
20. Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions.
Delgado M; Ganea D
Amino Acids; 2013 Jul; 45(1):25-39. PubMed ID: 22139413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
